# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Neurofibromatosis type 2

Neurofibromatosis 2 (NF2)Bilateral Acoustic NeurofibromatosisBANF Acoustic Neurinoma
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 11-14 of 14 results.
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Status: Recruiting
Last Changed: Nov 18, 2019
First Received: Apr 03, 2015
Disease(s): Neurofibromatosis 1, Plexiform Neurofibromas (PN)
Intervention(s): Selumetinib
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Status: Recruiting
Last Changed: Nov 26, 2019
First Received: May 24, 2019
Disease(s): Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)
Intervention(s): PD-0325901 oral capsule
Locations: SpringWorks' Site, Birmingham, Alabama, United States
SpringWorks' Site, Phoenix, Arizona, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
SpringWorks' Site, Los Angeles, California, United States
SpringWorks' Site, Los Angeles, California, United States
... and 37 other locations.
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Status: Recruiting
Last Changed: Dec 10, 2019
First Received: Jul 21, 2016
Disease(s): Cutaneous Neurofibroma, Neurofibromatosis Type 1, Optic Nerve Glioma
Intervention(s): Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Status: Recruiting
Last Changed: Nov 13, 2019
First Received: Jun 19, 2017
Disease(s): Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1
Intervention(s): Laboratory Biomarker Analysis, Pharmacological Study, Trametinib
Locations: Children's Hospital of Alabama, Birmingham, Alabama, United States
Phoenix Childrens Hospital, Phoenix, Arizona, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Kaiser Permanente Downey Medical Center, Downey, California, United States
Loma Linda University Medical Center, Loma Linda, California, United States
... and 46 other locations.